Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Myriad Genetic Laboratories, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
Clinically localized (no evidence on clinical or imaging studies of advanced disease.
No hormonal therapy including LHRH agonist or antagonist, anti-androgen, 5-alpha reductase inhibitor, estrogens or exogenous androgens, when applicable.
Sufficient amount of tissue remains from biopsy to perform genomic testing.
You may not be if
Patients with known history of hypogonadism will be excluded from the registry
Clareo Health | Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
